Cingulate (CING) Akcie Kurz

Cingulate Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Kansas City, Kansas and currently employs 15 full-time employees. The company went IPO on 2021-10-07. Cingulate Inc. is a biopharmaceutical company. The firm is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improve the lives of patients suffering from a multitude of commonly diagnosed conditions. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).